Clinical trials: Advanced Solid Tumors Patients
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Advanced Solid Tumor
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors.
- Trial name
- NCT05204862
- Testing
- TU2218, Anti-PD-1 antibody
- Where
- 3 sites in United States, South Korea
- Volunteers
- 240 people
- Sponsor
- TiumBio Co., Ltd.
Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
- Trial name
- DUAL-NK-BC (NCT07486089)
- Testing
- Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Solid Tumors
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
- Trial name
- NCT00882180
- Testing
- ALN-VSP02
- Where
- 10 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Alnylam Pharmaceuticals
Locally Advanced and Metastatic Solid Tumors
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217…
- Trial name
- NCT04047862
- Testing
- Ociperlimab, Tislelizumab, Pemetrexed
- Where
- 65 sites in United States, Australia and 4 more
- Volunteers
- 446 people
- Sponsor
- BeiGene
Advanced or Metastatic Solid Tumors
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor
- Trial name
- NCT04427774
- Testing
- Surufatinib plus Sintilimab
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Solid Tumors, Lymphoma
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12 by describing dose-limiting toxicities (DLTs), and thereby establishing the…
- Trial name
- NCT00978523
- Testing
- AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Arno Therapeutics
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Advanced Solid Tumors
A Trial of TAS-114 in Combination With S-1
A Phase I, Open-Label, International, Multicenter, Non-Randomized, Dose-Escalating Safety, Tolerance and Pharmacokinetic Study of Oral Administration of TAS-114 in Combination with S-1 in a Twice Daily Schedule for 14 Days in…
- Trial name
- NCT02454062
- Testing
- TAS-114, S-1
- Where
- 5 sites in Belgium, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumors
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
- Trial name
- NCT00768391
- Testing
- IMC-3G3
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Tumor, Metastatic Solid Tissue Tumors
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct…
- Conditions
- Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer
- Trial name
- NCT01882946
- Testing
- DCVax-Direct
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwest Biotherapeutics
Clear-Cell Renal Cell Carcinoma
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment…
- Trial name
- NCT04518046
- Testing
- Sitravatinib, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Solid Tumor
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04914286
- Testing
- GFH018, Toripalimab
- Where
- 3 sites in Australia, China
- Volunteers
- 148 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Patients With Advanced Stage Solid Tumors
Phase I Study of Hemay102 in Patients With Advanced Solid Tumors
This trial was a single-center, open-label, dose-increasing Phase I clinical study with subjects enrolled in patients with advanced solid tumors who failed standard treatment or who were unable to receive effective treatment.
- Trial name
- NCT03982303
- Testing
- Hemay102
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Hemay Oncology Pharmaceutical Co., Ltd
Metastatic Solid Tumors
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
The aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose).
- Trial name
- NCT00827203
- Testing
- Elesclomol Sodium
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Synta Pharmaceuticals Corp.
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Advanced or Metastatic Solid Tumors
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with…
- Trial name
- NCT07702955
- Testing
- KGX105 injection
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Advanced Solid Tumors
A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
The aim of this study is to determine the safety, tolerability and anti-tumoral activity of autologous T cells transduced with a T cell receptor specific for MAGE-A1 in eligible patients with advanced solid tumors.
- Trial name
- IMAG1NE (NCT05430555)
- Testing
- Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
- Where
- 14 sites in Belgium, Germany and 3 more
- Volunteers
- 23 people
- Sponsor
- T-knife GmbH
Advanced Solid Malignancy, Advanced Solid Tumor
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in Japanese patients with advanced solid…
- Trial name
- NCT01353781
- Testing
- AZD5363
- Where
- Japan
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.